A San Diego-based biotech has exited stealth mode with hopes of treating cancers that are resistant to current therapies. On Tuesday, 858 Therapeutics launched with a $60 million Series A financing round under its belt.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,